Abstract:

Cervical cancer is preventable using vaccines given to adolescents in three doses. The affordability of these vaccines and people’s willingness to pay (WTP) could affect the uptake of the vaccines, especially in developing countries. The study aimed to determine the willingness to pay for the vaccines and identify the factors associated with different levels of WTP among the participants. A cross-sectional study of 377 female teachers in the Enugu metropolis was undertaken between July and October 2017. A structured pre-tested interviewer-administered questionnaire was utilized for the collection of data. Willingness to pay was determined by the contingent valuation method utilizing the bidding game technique to estimate the maximum amount each participant would pay for the three doses of the HPV vaccine. Data were analyzed using SPSS version 20. The average monthly income of the participants was 152.18 USD (₦56307.91), with a range of 5.41-2162.16 USD (₦2,000 – 800,000). A considerable proportion (74.3%) of the respondents was willing to pay out of pocket for the vaccine. The average maximum willingness to pay for the three doses of the bivalent vaccine was 15USD, far below 63USD, which was the lowest cost for the three doses of the vaccine in Nigeria. Small family size (P<0.05) and high husband’s monthly income (P<0.05) were significantly associated with increased willingness to pay for cervical cancer vaccine by the participants. In conclusion, the willingness to pay for the cervical cancer vaccine among the participants was high but at a lower average cost than it currently goes for in Nigeria.

References:

[1] Castellsagué X, Sanjosé de S, Aguado T, Louie K, Bruni I, Muñoz J, et al., 2007, HPV and Cervical Cancer in the World Report. Vaccine [Internet], 25(3):C1–26, www.who.int/hpvcentre.

[2] Griffiths M., 2002, Screening for cervical cancer in developing countries. [Internet]. World Health Organization, http://screening.iarc.fr/doc/cervical_cancer_screening_in_dev_countries.pdf.

[3] Monsonego J., 2007, Prévention du cancer du col utérin (II): vaccination HPV prophylactique, connaissances actuelles, modalités pratiques et nouveaux enjeux. Presse Med [Internet], 36(4):640–66, http://www.ncbi.nlm.nih.gov/pubmed/17350792.

[4] PhRMA, 2016, A Decade of Innovation in Cancer:2006-2016 [Internet], www.phrma.org.

[5] Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al., 2004, Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet [Internet], 364(9447):1757–65, http://www.ncbi.nlm.nih.gov/pubmed/15541448.

[6] Villa LL, Ault KA, Giuliano AR, Costa RLR, Petta CA, Andrade RP, et al. 2006, Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine [Internet], 24(27–28):5571–83, http://www.ncbi.nlm.nih.gov/pubmed/16753240.

[7] Harper DM, Franco EL, Wheeler CM, Moscicki A-B, Romanowski B, Roteli-Martins CM, et al., 2017 Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. www.thelancet.com [Internet]. https://pdfs.semanticscholar.org/ead8/931b56deb09d4b7087c9808d2b85b8b69b83.pdf.

[8] Villa LL., 2008, Introduction of HPV prophylactic vaccines: a new challenge for Public Health in the 21st century. Rev Bras Epidemiol [Internet], 11(3):516–516, http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-790X2008000300019&lng=en&nrm=iso&tlng=en.

[9] Cutts F, Franceschi S, Goldie S, Castellsague X, de Sanjose S, Garnett G, et al., 2007, Human papillomavirus and HPV vaccines: a review. Bull World Health Organ [Internet], 85(9), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2636411/pdf/06-038414.pdf.

[10] Saxenian H, Cornejo S, Thorien K, Hecht R, Schwalbe N., 2011, An Analysis of How the GAVI Alliance and Low- And Middle-Income Countries Can Share Costs of New Vaccines. Health Aff [Internet], 30(6):1122–33, http://www.ncbi.nlm.nih.gov/pubmed/21653966.

[11] Graham JE, Mishra A., 2011, Global challenges of implementing human papillomavirus vaccines. Int J Equity Health [Internet], 10(1):27, http://www.scopus.com/inward/record.url?eid=2-s2.0-79959680444&partnerID=tZOtx3y1.

[12] Ngorsuraches S, Nawanukool K, Petcharamanee K, Poopantrakool U., 2015, Parents’ preferences and willingness-to-pay for human papilloma virus vaccines in Thailand. J Pharm Policy Pract [Internet], http://dx.doi.org/10.1186/s40545-015-0040-8.

[13] Umeh IB, Nduka SO, Ekwunife OI, Goldie S, O’Shea M, Campos N, et al., 2016, Mothers’ willingness to pay for HPV vaccines in Anambra state, Nigeria: a cross sectional contingent valuation study. Cost Eff Resour Alloc [Internet], 14(1):8, http://resource-allocation.biomedcentral.com/articles/10.1186/s12962-016-0057-0.

[14] Wigle J, Coast E, Watson-Jones D., 2013, Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine [Internet], 31(37):3811–7, http://www.ncbi.nlm.nih.gov/pubmed/23777956.

[15] Goldie SJ, Levin C, Mosqueira-Lovón NR, Ortendahl J, Kim J, O’Shea M, et al. 2012, Health and economic impact of human papillomavirus 16 and 18 vaccination of preadolescent girls and cervical cancer screening of adult women in Peru. Rev Panam Salud Publica/Pan Am J Public Heal [Internet], 32(6):426–34, http://www.ncbi.nlm.nih.gov/pubmed/23370186.

[16] Kale OO BA., 1991, Methods of Epidemiological Studies. In: MA B, editor. Handbook of Research Methods in Medicine. 1st ed. Lagos: Nigerian Educational Research & Development Council (NERDC), 67 – 76.

[17] Chilton S., 2007, Contingent Valuation and Social Choices Concerning Public Goods: An Overview of Theory, Methods and Issues. Rev Econ Polit [Internet]. 117(5):655, http://www.cairn.info/revue-d-economie-politique-2007-5-page-655.htm.

[18] Hoyos D, Mariel P., 2010, Contingent valuation: past, present and future, 07:329–43.

[19] Alder S, Gustafsson S, Perinetti C, Mints M, Sundström K, Andersson S., 2015, Mothers’ acceptance of human papillomavirus (HPV) vaccination for daughters in a country with a high prevalence of HPV. Oncol Rep [Internet]., 33(5):2521–8, http://www.ncbi.nlm.nih.gov/pubmed/25738832.

[20] Ugwu E, Obi S, Ezechukwu P, Okafor I, Ugwu A., 2013, Acceptability of human papilloma virus vaccine and cervical cancer screening among female health-care workers in Enugu, Southeast Nigeria. Niger J Clin Pract [Internet], 16(2):249, http://www.njcponline.com/text.asp?2013/16/2/249/110141.

[21] Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S., 2014, Barriers to human papillomavirus vaccination among US adolescents: a
systematic review of the literature. JAMA Pediatr [Internet], 168(1):76–82, http://www.ncbi.nlm.nih.gov/pubmed/24276343.

[22] Ezenwa BN, Balogun MR, Okafor IP., 2013, Mothers’ human papilloma virus knowledge and willingness to vaccinate their adolescent daughters in Lagos, Nigeria. Int J Womens Health [Internet], 5:371–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23874123.

[23] Iliyasu Z, Abubakar IS, Aliyu MH, Galadanci HS., 2010, Cervical cancer risk perception and predictors of human papilloma virus vaccine acceptance among female university students in northern Nigeria. J Obstet Gynaecol (Lahore) [Internet], 30(8):857–62.

http://www.tandfonline.com/doi/full/10.3109/01443615.2010.511724.

[24] Kruiroongroj S, Thavorncharoensap M., 2014, Knowledge, Acceptance, and Willingness to Pay for Human Papilloma Virus (HPV) Vaccination among Female Parents in Thailand, 15:5469–74.

[25] Cerda AA, García LY, Gaete FI, Pizarro TH., 2013, Willingness to pay for human papillomavirus vaccine in Metropolitan Santiago, Chile. Rev Med Chil [Internet], 141(2):167–72, https://pubmed.ncbi.nlm.nih.gov/23732488/.

[26] Kannan MM, Kingston R, Num SK, Chin NS, Yong J, Lui Y, et al., 2015, Health Professional Students’ Willingness to Pay for Human Papillomavirus Vaccination and Factors Influencing Their Decision in Malaysia. Virus Disease, https://doi.org/10.1016/j.jval.2015.09.1274.